Literature DB >> 6429720

Israel's prevention programs and screening policies for cardiovascular disease.

L Epstein.   

Abstract

For all four broad ethnic groups in Israel, mortality rates declined over the last decade for both ischemic heart disease (IHD) and cerebrovascular disease (CVD), the first and third most important causes of death in the country. The four broad ethnic groups consist of persons born in Israel, Asia, North Africa, and Europe. Mortality data also indicate a low male to female ratio in mortality from IHD, a definite female predominance in mortality from CVD, and high mortality rates for IHD and CVD in males and females born in North Africa. Morbidity data, especially incidence, are scarce for CVD in both sexes and IHD in females. The feasibility of preventive intervention needs to be tested under the specific conditions of Israel. Although a multiple risk factor trial in Jerusalem showed that such a program can be conducted in a primary care framework, it clearly still needs to be tested in clinics rather than in a model teaching institution. The best place for intervention would seem to be the primary health care system, which has almost complete access to the country's population. Kupat Holim (the Health Insurance Institute of the General Federation of Labour) is attempting systematically to identify and manage hypertension patients. To date, management of acute coronary disease has been emphasized in Israel. Although additional resources are needed for primary prevention services, other options are suggested for obtaining those services.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6429720      PMCID: PMC1424557     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  27 in total

1.  Coronary heart disease and hypertension among Jews immigrated to Israel from the Atlas Mountain region of North Africa.

Authors:  F DREYFUSS; P HAMOSH; Y G ADAM; B KALLNER
Journal:  Am Heart J       Date:  1961-10       Impact factor: 4.749

2.  Atherosis and related factors in immigrants to Israel.

Authors:  M TOOR; A KATCHALSKY; J AGMON; D ALLALOUF
Journal:  Circulation       Date:  1960-08       Impact factor: 29.690

3.  Myocardial infarction over a five-year period. I. Prevalence, incidence and mortality experience.

Authors:  J H Medalie; H A Kahn; H N Neufeld; E Riss; U Goldbourt; T Perlstein; D Oron
Journal:  J Chronic Dis       Date:  1973-02

4.  Ischemic heart disease in Israel: changes over 30 years.

Authors:  L Epstein
Journal:  Isr J Med Sci       Date:  1979-12

5.  Mortality and the multiple risk factor intervention trial.

Authors:  R A Stallones
Journal:  Am J Epidemiol       Date:  1983-06       Impact factor: 4.897

6.  [Open heart surgery--past, present and future].

Authors:  D Goor
Journal:  Harefuah       Date:  1980-12-01

7.  [Recent trends of declining cardiovascular, cerebrovascular and total mortality in Israel (1974-1978)].

Authors:  U Goldbourt; H N Neufeld
Journal:  Harefuah       Date:  1980

8.  Plasma cholesterol, triglyceride and high-density lipoprotein-cholesterol levels in 17-year-old Jerusalem offspring of Jews from 19 countries of birth.

Authors:  S T Halfon; S Eisenberg; M Baras; A M Davies; G Halperin; Y Stein
Journal:  Isr J Med Sci       Date:  1982-11

9.  Serum cholesterol, electrophoretic lipid pattern, diet and coronary artery disease: a study in coronary patients and in healthy men of different origin and occupations in Israel.

Authors:  D BRUNNER; K LOBL
Journal:  Ann Intern Med       Date:  1958-10       Impact factor: 25.391

10.  Variation in the sex ratio in cardiovascular mortality.

Authors:  S L Kark
Journal:  Isr J Med Sci       Date:  1976-10
View more
  1 in total

1.  Shifting the distribution of risk: results of a community intervention in a Swedish programme for the prevention of cardiovascular disease.

Authors:  L Weinehall; G Westman; G Hellsten; K Boman; G Hallmans; T A Pearson; S Wall
Journal:  J Epidemiol Community Health       Date:  1999-04       Impact factor: 3.710

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.